How far along is the industry in making these low weight molecular compounds for CCR5?
Several companies now are placing major efforts into developing small molecular weight molecules that will block CCR5 and prevent HIV from using them. Some of them have entered clinical trials. There’s some hint of promise and with drugs of this type what we’re going to see are first generation, second generation, third generation variances that have improved potency with fewer side effects. These are going to have to go through a long period of development including clinical trials to test safety and efficacy. But there’s a real hope that this would provide another tool or another weapon in the armamentarium against HIV. With a virus like HIV that can change so fast, you want to be able to throw different kinds of things at it. So the idea of having a new kind of target different from the ones that are already being successfully used like the transcriptase inhibitors and the protease inhibitors, has become very, very exciting. This idea of an entry inhibitor that blocks the coreceptor
Related Questions
- Is it possible to obtain coverage for low molecular weight heparin (LMWH) for treatment of venous thromboembolism (VTE) in cancer patients?
- What is the difference between Coamatic Heparin, Coatest Heparin, Coatest and Low Molecular Weight Heparin / Heparin?
- How far along is the industry in making these low weight molecular compounds for CCR5?
